Skip to content

Home Map The News Technology Politics Business Sports Entertainment

Global AI-Powered News Intelligence. Real-time headlines, mapped by continent and country, from authoritative sources worldwide.

Powered by AI

Navigate

Home
Map The News
About
Search

Sections

Technology
Politics
Business
Sports
Entertainment

More

Privacy
Contact
Sitemap
Robots

© 2026 newsGlobal. All rights reserved.

Headlines refresh every 10 minutes.

Home Map Search Topics About

Home / Business

UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy

Bloomberg

BusinessBloomberg·Jun 17, 2026·1 min read

UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy

UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.

View original source — Bloomberg ↗

ShareShare on X Share on Facebook

Related stories

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

BusinessJun 17, 2026 · 1 min

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

BusinessJun 5, 2026 · 1 min

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

TechnologyJun 17, 2026 · 1 min

"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

BusinessJun 8, 2026 · 1 min

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug